Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
CLL Treatment Update: ASCO & EHA 2026 Highlights #CLL | EHA 2026
HealthTreeDescription
Dr. Jennifer Woyach highlights three major CLL breakthroughs from ASCO and EHA 2026 conferences.
THREE KEY UPDATES:
1. BRUIN CLL-322: Relapsed CLL Trial
New treatment options for patients whose CLL returns after initial therapy. Important data for those who've already tried first-line treatments.
2. CLL14 Final Results: Venetoclax + Obinutuzumab
Long-term outcomes from combining two proven drugs in newly diagnosed patients. Shows how well this combination works over time.
3. Sonrotoclax + Zanibrutinib
Emerging data on a new drug combination approach. Represents the next generation of CLL therapies in development.
WHY THIS MATTERS:
CLL treatment keeps improving with new options becoming available. These updates show progress in both first-line and relapsed disease settings, giving patients more hope and more choices.
WATCH THIS TO:
Learn about the latest CLL treatment advances directly from an expert. Understand new options that may become available for your care.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction
0:23 BRUIN CLL-322: New Options for Relapsed CLL
1:17 CLL14 Final Results: Venetoclax + Obinutuzumab
1:33 Sonrotoclax + Zanibrutinib: Emerging Data
1:50 Closing
#CLL #ClinicalUpdate #ASCO2026 #EHA2026 #BloodCancer